Balchem Corporation

Business overview

Balchem develops, manufactures, distributes and markets specialty performance ingredients and products across Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products (SP). Additional activities are reported as "Other and Unallocated" in consolidated results.

Core capabilities include spray drying and emulsification, extrusion and agglomeration, encapsulation technologies, and mineral chelation (e.g., Metalosate) used as raw materials in nutrition, animal health, and agricultural applications. The company serves customers such as contract sterilizers, medical device manufacturers, nut/meat processors, and beverage and dairy producers, with manufacturing and distribution across multiple regions.

Segments and key product areas

• Human Nutrition and Health (HNH)

  • Human-grade choline nutrients
  • Mineral amino acid chelates, specialized mineral salts and complexes
  • Vitamin K2
  • Methylsulfonylmethane (MSM) for joint health, sports nutrition, skin and aging
  • Microencapsulation and delivery systems for fortified foods and beverages
  • Cereal systems for ready-to-eat cereals and grain-based ingredients

• Animal Nutrition and Health (ANH)

  • Choline chloride (dry and aqueous forms) for poultry, pet and swine
  • MSM for animal health
  • Microencapsulated nutrient products and chelated minerals to improve absorption

• Specialty Products (SP)

  • Repackaged gases and chemicals: ethylene oxide (EtO) for sterilization and spice fumigation; propylene oxide as a fumigant; ammonia for industrial uses
  • Single-use canisters for sterilization of reusable devices
  • Micronutrient agricultural nutrition via Metalosate chelated minerals

Operational and market context

• Raw materials are sourced globally and include petrochemicals, minerals, metals and agricultural commodities; prices and supply chains are subject to fluctuation.
• Regulatory environment includes EPA FIFRA registrations for EtO and PPO; environmental and health and safety compliance are ongoing priorities, with active EPA reviews and related mitigation measures.
• The company emphasizes research and development to differentiate products through data, intellectual property and customer value, with ongoing product development and process improvements.

People, locations and governance

• Employees: approximately 1,352 full-time employees worldwide as of December 31, 2025; about 16% are covered by collective-bargaining agreements.
• Locations: 38 principal locations worldwide for manufacturing, warehousing and administrative functions.
  • HNH footprint example: 11 U.S. cities and 6 foreign countries; 1 administrative, 16 manufacturing and 7 warehousing facilities (plus corporate)
  • ANH footprint example: 6 U.S. cities and 1 foreign country; 8 manufacturing facilities listed
  • SP footprint example: 4 U.S. cities and 5 foreign countries; 7 manufacturing facilities listed
• Leadership (as of Feb 20, 2026)
  • Theodore L. Harris — Chairman, President and CEO
  • C. Martin Bengtsson — EVP and CFO
  • Hatsuki Miyata — EVP, General Counsel and Secretary
  • Frederic Boned — SVP, GM of HNH; Head of Digital Transformation and AI
  • George Graham — SVP and Chief R&D Officer
  • Martin L. Reid — SVP and Chief Supply Chain Officer
  • M. Brent Tignor — SVP and Chief Human Resources Officer
  • Job L. van Gunsteren — SVP and GM, SP

Financial and operational highlights

• Backlog (orders to be fulfilled)

  • December 31, 2025: Total backlog $53,365 thousand
    • HNH: $39,587
    • ANH: $11,489
    • SP: $1,933
    • Other: $356
  • December 31, 2024: Total backlog $50,415 thousand
    • HNH: $39,959
    • ANH: $9,035
    • SP: $1,284
    • Other: $137
  • All backlog is expected to be filled in fiscal year 2026.

• Capital expenditures (capex)

  • 2025: $43,193 thousand
    • $18,820 related to capacity expansion and efficiency projects (HNH and ANH)
    • $5,147 for environmental, health, safety and security upgrades
  • 2024: $35,148 thousand
  • 2023: $37,274 thousand
  • 2026 guidance: $40,000 to $45,000 thousand

• Research and development (company-sponsored)

  • 2025: approximately $18,510 thousand
  • 2024: approximately $16,793 thousand
  • 2023: approximately $15,049 thousand

• Intellectual property

  • Over 130 patents
  • Over 400 registered trademarks (U.S. and overseas)

• Seasonality

  • HNH and consumer-focused products are generally not seasonal
  • SP (plant nutrition) is seasonal, with most sales in the first half of the year

• Environmental and regulatory matters

  • Ongoing EPA FIFRA-related reviews for EtO and PPO
  • Verona, Missouri facility is subject to remediation and a remedial investigation/feasibility study under an ASAOC related to a historical Superfund site